Rx Sales Incentives Should Encourage Risk Education, AMA Tells FDA
Executive Summary
Pharmaceutical companies should provide incentives to sales reps to detail drug risk information, the American Medical Association suggested during a May 22 FDA hearing on risk management
You may also be interested in...
Pharmacy Risk Management Wish-List: “Opt-In” Feature, “Core Protocols”
Limited distribution programs for pharmaceuticals should include an "opt-in" feature to allow participation of any qualified pharmacy, the American Pharmaceutical Association told FDA during a May 22 hearing on risk management
Pharmacy Risk Management Wish-List: “Opt-In” Feature, “Core Protocols”
Limited distribution programs for pharmaceuticals should include an "opt-in" feature to allow participation of any qualified pharmacy, the American Pharmaceutical Association told FDA during a May 22 hearing on risk management
Pfizer “Toolkit” Proposal Focuses On Adverse Event Signals
Pfizer is proposing that the PhRMA/FDA "toolkit" working group focus on methods to gather more reliable signals of adverse events as a precursor to an improved risk management system